AR082471A1 - Poblacion de microparticulas que comprenden corticoesteroides, preparacion de liberacion controlada, formulacion, metodo de elaboracion - Google Patents
Poblacion de microparticulas que comprenden corticoesteroides, preparacion de liberacion controlada, formulacion, metodo de elaboracionInfo
- Publication number
- AR082471A1 AR082471A1 ARP110102807A ARP110102807A AR082471A1 AR 082471 A1 AR082471 A1 AR 082471A1 AR P110102807 A ARP110102807 A AR P110102807A AR P110102807 A ARP110102807 A AR P110102807A AR 082471 A1 AR082471 A1 AR 082471A1
- Authority
- AR
- Argentina
- Prior art keywords
- population
- corticosteroid
- class
- microparticles
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
Abstract
Reivindicación 1: Una población de micropartículas que comprenden un corticoesteroide clase B, o una de sus sales farmacéuticamente aceptables, incorporado en una matriz de copolímero de ácido láctico-ácido glicólico, donde el corticoesteroide clase B representa entre 22% y 28% de las micropartículas.Reivindicación 5: La población de la reivindicación 1, la preparación de la reivindicación 2 o la formulación de la reivindicación 3, donde el copolímero de ácido láctico-ácido glicólico es un copolímero de ácido poli(láctico-co-glicólico) (PLGA). Reivindicación 6: La población de la reivindicación 1, la preparación de la reivindicación 2 o la formulación de la reivindicación 3, donde el corticoesteroide clase B es triamcinolona acetonida o un análogo químico comercial o una de sus sales farmacéuticamente aceptables. Reivindicación 12: Una población de micropartículas que comprenden un corticoesteroide clase A o una de sus sales farmacéuticamente aceptables, incorporado en una matriz de copolímero de ácido láctico-ácido glicólico, donde el corticoesteroide clase A representa entre 15% y 30% de las micropartículas. Reivindicación 17: La población de la reivindicación 12, la preparación de la reivindicación 13 o la formulación de la reivindicación 14, donde el corticoesteroide clase A es prednisolona o un análogo químico comercial o una de sus sales farmacéuticamente aceptables. Reivindicación 23: Una población de micropartículas que comprenden un corticoesteroide clase C, o una de sus sales farmacéuticamente aceptables, incorporado en una matriz de copolímero de ácido láctico-ácido glicólico, donde el corticoesteroide clase C representa entre 15% y 30% de las micropartículas. Reivindicación 28: La población de la reivindicación 23, la preparación de la reivindicación 24 o la formulación de la reivindicación 25, donde el corticoesteroide clase C es betametasona o un análogo químico comercial, o una de sus sales farmacéuticamente aceptables. Reivindicación 34: Una población de micropartículas que comprenden un corticoesteroide clase D, o una de sus sales farmacéuticamente aceptables, incorporado en una matriz de copolímero de ácido láctico-ácido glicólico, donde el corticoesteroide clase D representa entre 8% y 20% de las micropartículas. Reivindicación 39: La población de la reivindicación 34, la preparación de la reivindicación 35 o la formulación de la reivindicación 36, donde el corticoesteroide clase D es fluticasona propionato, fluticasona, o un análogo químico comercial o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37066610P | 2010-08-04 | 2010-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR082471A1 true AR082471A1 (es) | 2012-12-12 |
Family
ID=45559826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110102807A AR082471A1 (es) | 2010-08-04 | 2011-08-03 | Poblacion de microparticulas que comprenden corticoesteroides, preparacion de liberacion controlada, formulacion, metodo de elaboracion |
Country Status (23)
Country | Link |
---|---|
US (8) | US20120282298A1 (es) |
EP (2) | EP3701941A1 (es) |
JP (3) | JP5873492B2 (es) |
KR (2) | KR101927551B1 (es) |
CN (2) | CN107669640A (es) |
AR (1) | AR082471A1 (es) |
AU (1) | AU2011285691B2 (es) |
BR (1) | BR112013002601A2 (es) |
CA (2) | CA2807150C (es) |
CL (1) | CL2013000347A1 (es) |
CO (1) | CO6700827A2 (es) |
ES (1) | ES2799419T3 (es) |
IL (1) | IL224547B (es) |
MX (1) | MX353466B (es) |
MY (1) | MY171929A (es) |
NZ (1) | NZ607797A (es) |
RU (2) | RU2642279C2 (es) |
SG (3) | SG10201602789XA (es) |
TW (2) | TWI630001B (es) |
UA (1) | UA111162C2 (es) |
UY (1) | UY33546A (es) |
WO (1) | WO2012019009A1 (es) |
ZA (1) | ZA201300831B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA111162C2 (uk) * | 2010-08-04 | 2016-04-11 | Флекшен Терап'Ютікс, Інк. | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю |
EP2701687B1 (en) | 2011-04-25 | 2016-09-21 | Shandong Luye Pharmaceutical Co., Ltd. | Risperidone sustained release microsphere composition |
EP3281631A1 (en) * | 2011-08-04 | 2018-02-14 | Flexion Therapeutics, Inc. | Corticosteroids for the treatment of joint pain |
US8927529B2 (en) | 2012-01-30 | 2015-01-06 | SpineThera | Treatment of back pain by injection of microparticles of dexamethasone acetate and a polymer |
US9833460B2 (en) * | 2013-01-23 | 2017-12-05 | Semnur Pharmaceuticals, Inc. | Pharmaceutical formulation |
ES2697696T3 (es) * | 2013-03-15 | 2019-01-25 | Oakwood Laboratories LLC | Microesferas de liberación sostenida y método de producción de las mismas |
WO2014153384A1 (en) * | 2013-03-19 | 2014-09-25 | Flexion Therapeutics, Inc. | Corticosteroid formulations for the treatment of joint pain and methods of use thereof |
AU2014235854B2 (en) * | 2013-03-21 | 2019-04-11 | Eupraxia Pharmaceuticals USA LLC | Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith |
WO2015018461A1 (fr) * | 2013-08-09 | 2015-02-12 | Genbiotech | Compositions therapeutiques comprenant d'acide hyaluronique |
KR20160091960A (ko) * | 2013-11-27 | 2016-08-03 | 에티컨, 엘엘씨 | 정밀하게 제어가능한 흡수 속도를 갖는 흡수성 중합체 블렌드 조성물, 가공 방법, 및 그로부터의 치수 안정한 의료 장치 |
CN106132399B (zh) * | 2014-04-08 | 2020-05-12 | 帝斯曼知识产权资产管理有限公司 | 用于治疗关节炎病症的可生物降解的聚酯酰胺 |
TW202245791A (zh) | 2015-01-21 | 2022-12-01 | 美商桑紐爾製藥公司 | 醫藥配方 |
US10322169B2 (en) | 2015-06-10 | 2019-06-18 | Evonik Roehm Gmbh | Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer |
HUE063850T2 (hu) | 2015-09-21 | 2024-02-28 | Teva Pharmaceuticals Int Gmbh | Hosszan tartó felszabadulású olanzapin készítmények |
TW201726145A (zh) * | 2015-10-13 | 2017-08-01 | 弗萊斯恩醫療公司 | 用於維持皮質類固醇滑液濃度之皮質類固醇調配物 |
ES2672993T3 (es) | 2015-10-27 | 2018-06-19 | Eupraxia Pharmaceuticals Inc. | Formulaciones de liberación sostenida de anestésicos locales |
US20170258815A1 (en) * | 2016-03-14 | 2017-09-14 | Flexion Therapeutics, Inc. | Corticosteroid formulations and methods for the treatment of joint pain in patients with diabetes |
WO2018112408A1 (en) * | 2016-12-15 | 2018-06-21 | Flexion Therapeutics, Inc. | Fluticasone formulations and methods of use thereof |
CN106727358A (zh) * | 2017-01-24 | 2017-05-31 | 广州帝奇医药技术有限公司 | 阿立哌唑及其衍生物的缓释组合物与该缓释组合物的制备方法 |
CN106983733A (zh) * | 2017-03-08 | 2017-07-28 | 江苏富泽药业有限公司 | 曲安奈德plga缓释微球注射剂、其制备方法及其在制备治疗骨关节炎疼痛药物中的应用 |
US20200009156A1 (en) * | 2017-03-17 | 2020-01-09 | Flexion Therapeutics, Inc. | Fluticasone extended-release formulations and methods of use thereof |
CA3057438A1 (en) | 2017-03-20 | 2018-09-27 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulaitons |
KR102101969B1 (ko) * | 2017-09-06 | 2020-04-22 | (주)인벤티지랩 | 목시덱틴을 포함하는 마이크로 입자 및 이의 제조 방법 |
US20190336511A1 (en) * | 2018-05-02 | 2019-11-07 | Georgiy Brusovanik | Treatment for Inflammation and Pain with Reduced Gastro-Intestinal Side Effects Combining Methylprednisolone, Paracetamol, and Lansoprazole |
SG11202100054YA (en) * | 2018-07-09 | 2021-02-25 | Taiwan Liposome Co Ltd | Methods to reduce complications of intra-articular steroid |
RU2703257C1 (ru) * | 2018-12-04 | 2019-10-16 | Закрытое акционерное общество "СКАЙ ЛТД" | Способ лечения воспалительных процессов суставов и простатита |
CN109700770B (zh) * | 2019-01-31 | 2021-02-12 | 浙江圣兆药物科技股份有限公司 | 一种曲安奈德微球制剂及其制备方法 |
KR102377975B1 (ko) * | 2019-03-19 | 2022-03-23 | (주)리젠바이오텍 | 스테로이드계 약물을 포함하는 생분해성 고분자 미세입자 및 이의 제조 방법 |
CN112955129A (zh) * | 2019-03-19 | 2021-06-11 | 瑞珍生物科技株式会社 | 包含类固醇类药物的生物降解性高分子微粒及其制备方法 |
WO2020227353A1 (en) * | 2019-05-06 | 2020-11-12 | Fordoz Pharma Corp. | Injectable sustained-release formulations for treatment of joint pain and inflammation |
AU2020283135A1 (en) * | 2019-05-31 | 2022-01-06 | Dose Medical Corporation | Bioerodible polyester polymer implants and related methods of use |
CN110237052B (zh) * | 2019-07-11 | 2021-07-13 | 苏州大学 | 一种醋酸曲安奈德缓释微球及其制备方法 |
CN111803647A (zh) * | 2020-08-14 | 2020-10-23 | 山东谷雨春生物科技有限公司 | 一种治疗退行性关节炎的药物及其制备方法 |
WO2022153262A1 (en) | 2021-01-18 | 2022-07-21 | Anton Frenkel | Pharmaceutical dosage form |
GB202104224D0 (en) | 2021-03-25 | 2021-05-12 | Medincell | Pharmaceutical composition |
EP4313021A1 (en) * | 2021-03-26 | 2024-02-07 | The Regents Of The University Of California | Immunoregulatory microparticles for modulating inflammatory arthritides |
WO2022219089A1 (en) | 2021-04-16 | 2022-10-20 | Fondazione Istituto Italiano Di Tecnologia | Polymeric microparticles for the local treatment of chronic inflammatory diseases |
CA3227324A1 (en) | 2021-07-06 | 2023-01-12 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4293539A (en) | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
US4530840A (en) * | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US5700485A (en) * | 1992-09-10 | 1997-12-23 | Children's Medical Center Corporation | Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid |
DK0724433T3 (da) | 1993-10-22 | 1999-08-30 | Genentech Inc | Fremgangsmåde til fremstilling af mikrosfærer med et tørringstrin i fluidiseret leje |
EP1649850A1 (en) | 1993-11-19 | 2006-04-26 | Alkermes Controlled Therapeutics Inc. II | Preparation of biodegradable microparticles containing a biologically active agent |
DE69841984D1 (de) | 1997-09-05 | 2010-12-16 | Maruho K K | Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen |
JPH11222425A (ja) * | 1997-10-27 | 1999-08-17 | Ss Pharmaceut Co Ltd | 関節疾患治療用関節内投与製剤 |
TW577758B (en) * | 1997-10-27 | 2004-03-01 | Ssp Co Ltd | Intra-articular preparation for the treatment of arthropathy |
US6726918B1 (en) * | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
US6824822B2 (en) | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
DE60120211T2 (de) | 2000-11-06 | 2007-04-12 | Asahi Kasei Kabushiki Kaisha | Zellulosepartikel für eine pharmazeutische zusammensetzung |
KR100446101B1 (ko) | 2000-12-07 | 2004-08-30 | 주식회사 삼양사 | 수난용성 약물의 서방성 제형 조성물 |
ATE375145T1 (de) | 2000-12-21 | 2007-10-15 | Alrise Biosystems Gmbh | Induziertes phasenübergangs verfahren zur herstellung von hydrophile wirkstoffe enthaltende mikropartikeln |
US20040022853A1 (en) | 2001-04-26 | 2004-02-05 | Control Delivery Systems, Inc. | Polymer-based, sustained release drug delivery system |
JP2006503865A (ja) * | 2002-09-30 | 2006-02-02 | アキュスフィア, インコーポレイテッド | 吸入のための徐放性の多孔性微粒子 |
US20040121009A1 (en) | 2002-10-17 | 2004-06-24 | Alkermes Controlled Therapeutics, Inc. | Method of modifying the release profile of sustained release compositions |
AU2004222340B2 (en) | 2003-03-14 | 2009-11-12 | Intersect Ent, Inc. | Sinus delivery of sustained release therapeutics |
US20040224030A1 (en) * | 2003-05-06 | 2004-11-11 | Shastri Venkatram R. | Microsphere delivery systems |
EP1643970A2 (en) | 2003-06-09 | 2006-04-12 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of growth hormone |
CA2533887A1 (en) * | 2003-09-30 | 2005-04-14 | Acusphere, Inc. | Injectable, oral, or topical sustained release pharmaceutical formulations |
US7456254B2 (en) * | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
US20090324678A1 (en) * | 2004-07-16 | 2009-12-31 | Spinal Restoration, Inc. | Methods and kits for treating joints and soft tissues |
US7758778B2 (en) | 2005-09-07 | 2010-07-20 | Southwest Research Institute | Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents |
US7261529B2 (en) | 2005-09-07 | 2007-08-28 | Southwest Research Institute | Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents |
AU2006287499A1 (en) | 2005-09-07 | 2007-03-15 | Eliot M. Slovin | Biodegradable microparticle pharmaceutical formulations exhibiting improved release rates |
US9693967B2 (en) * | 2005-09-07 | 2017-07-04 | Southwest Research Institute | Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates |
EP1986603A2 (en) | 2006-01-13 | 2008-11-05 | SurModics, Inc. | Microparticle containing matrices for drug delivery |
US20070298073A1 (en) * | 2006-06-23 | 2007-12-27 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
AU2007319577A1 (en) * | 2006-10-06 | 2008-05-22 | Baxter Healthcare S.A. | Microencapsules containing surface-modified microparticles and methods of forming and using the same |
US20080317805A1 (en) * | 2007-06-19 | 2008-12-25 | Mckay William F | Locally administrated low doses of corticosteroids |
US20090105142A1 (en) * | 2007-08-23 | 2009-04-23 | Genzyme Corporation | Treatment with kallikrein inhibitors |
US20110206773A1 (en) | 2008-05-20 | 2011-08-25 | Yale University | Sustained delivery of drugs from biodegradable polymeric microparticles |
US20110311630A1 (en) | 2008-06-09 | 2011-12-22 | Boehringer Ingelheim International Gmbh | Novel embedment particles for inhalation |
WO2010030868A1 (en) * | 2008-09-11 | 2010-03-18 | Surmodics Pharmaceuticals, Inc. | Solvent extraction microencapsulation with tunable extraction rates |
JP2012515791A (ja) | 2009-01-23 | 2012-07-12 | サーモディクス ファーマシューティカルズ, インコーポレイテッド | ポリマー混成物由来の放出制御システム |
EP2512487A4 (en) | 2009-12-15 | 2013-08-07 | THERAPEUTIC POLYMERNANOPARTICLES WITH CORTICOSTEROIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
UA111162C2 (uk) * | 2010-08-04 | 2016-04-11 | Флекшен Терап'Ютікс, Інк. | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю |
-
2011
- 2011-04-08 UA UAA201301676A patent/UA111162C2/uk unknown
- 2011-08-03 UY UY0001033546A patent/UY33546A/es not_active Application Discontinuation
- 2011-08-03 TW TW105118771A patent/TWI630001B/zh active
- 2011-08-03 TW TW100127548A patent/TWI548412B/zh active
- 2011-08-03 AR ARP110102807A patent/AR082471A1/es unknown
- 2011-08-04 CA CA2807150A patent/CA2807150C/en active Active
- 2011-08-04 MY MYPI2013000361A patent/MY171929A/en unknown
- 2011-08-04 AU AU2011285691A patent/AU2011285691B2/en active Active
- 2011-08-04 SG SG10201602789XA patent/SG10201602789XA/en unknown
- 2011-08-04 SG SG10201607891VA patent/SG10201607891VA/en unknown
- 2011-08-04 RU RU2013109362A patent/RU2642279C2/ru active
- 2011-08-04 KR KR1020137004667A patent/KR101927551B1/ko active IP Right Grant
- 2011-08-04 EP EP20170586.0A patent/EP3701941A1/en not_active Withdrawn
- 2011-08-04 WO PCT/US2011/046601 patent/WO2012019009A1/en active Application Filing
- 2011-08-04 BR BR112013002601A patent/BR112013002601A2/pt not_active Application Discontinuation
- 2011-08-04 NZ NZ607797A patent/NZ607797A/en unknown
- 2011-08-04 RU RU2018100114A patent/RU2018100114A/ru not_active Application Discontinuation
- 2011-08-04 CA CA2956556A patent/CA2956556A1/en not_active Abandoned
- 2011-08-04 KR KR1020187034479A patent/KR20180132159A/ko not_active Application Discontinuation
- 2011-08-04 EP EP11815323.8A patent/EP2600836B1/en active Active
- 2011-08-04 JP JP2013523336A patent/JP5873492B2/ja active Active
- 2011-08-04 CN CN201710992399.XA patent/CN107669640A/zh active Pending
- 2011-08-04 ES ES11815323T patent/ES2799419T3/es active Active
- 2011-08-04 CN CN201180047943.4A patent/CN103260603B/zh active Active
- 2011-08-04 SG SG2013007703A patent/SG187665A1/en unknown
- 2011-08-04 MX MX2013001433A patent/MX353466B/es active IP Right Grant
-
2012
- 2012-02-08 US US13/368,580 patent/US20120282298A1/en not_active Abandoned
- 2012-03-16 US US13/422,994 patent/US8828440B2/en active Active
-
2013
- 2013-01-31 ZA ZA2013/00831A patent/ZA201300831B/en unknown
- 2013-02-03 IL IL224547A patent/IL224547B/en active IP Right Grant
- 2013-02-04 CL CL2013000347A patent/CL2013000347A1/es unknown
- 2013-03-04 CO CO13043214A patent/CO6700827A2/es unknown
- 2013-12-16 US US14/107,188 patent/US20140242170A1/en not_active Abandoned
-
2014
- 2014-08-18 US US14/461,884 patent/US9555048B2/en active Active
- 2014-08-18 US US14/461,883 patent/US9555047B2/en active Active
-
2015
- 2015-09-09 JP JP2015177143A patent/JP2016028070A/ja not_active Ceased
-
2017
- 2017-01-31 US US15/420,829 patent/US20170135957A1/en not_active Abandoned
- 2017-03-15 US US15/459,961 patent/US9949987B2/en active Active
-
2018
- 2018-03-27 US US15/937,053 patent/US10624905B2/en active Active
- 2018-11-29 JP JP2018223009A patent/JP2019059752A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR082471A1 (es) | Poblacion de microparticulas que comprenden corticoesteroides, preparacion de liberacion controlada, formulacion, metodo de elaboracion | |
IL284913A (en) | A multispecific antigen-binding molecule that has the function-changing activity of a cofactor for blood coagulation factor viii (fviii), and a pharmaceutical formulation containing the molecule as an active ingredient | |
CO2018003558A2 (es) | Método de cristalización y biodisponibilidad | |
UA92030C2 (ru) | Фармацевтические композиции регулированного высвобождения нестабильных в кислой среде лекарственных средств | |
MX2020012310A (es) | Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas. | |
UY36761A (es) | Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma | |
FR2904219B1 (fr) | Microparticules a base de copolymere amphiphile et de principe(s) actif(s) a liberation modifiee et formulations pharmaceutiques en contenant | |
MA50189A (fr) | Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci | |
PH12019500061A1 (en) | Oral gastroretentive formulations and uses thereof | |
DK3604304T3 (da) | Pyrrolo-pyridinderivatforbindelse, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende denne som aktiv ingrediens til forebyggelse eller behandling af proteinkinase-relaterede sygdomme | |
EP3513789A3 (en) | Prophylactic and therapeutic agents for fgfr3 diseases | |
BR112022003895A2 (pt) | Sistema e método de entrega de múltiplos fármacos | |
EP3773671A4 (en) | METHODS AND COMPOSITIONS FOR RETARDED MICROPARTICLES FOR EYE DRUG DELIVERY | |
SG10201902407PA (en) | Injectable microparticles for hyper-localized release of therapeutic agents | |
SG11202004097RA (en) | Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic method | |
AR108233A1 (es) | Composiciones farmacéuticas orales de nicotinamida | |
AR096459A1 (es) | Composiciones de corticosteroides y método de fabricación | |
WO2020194087A3 (en) | Extended release pharmaceutical formulation | |
MA50394A (fr) | Formulations pharmaceutiques comprenant un agoniste de récepteur d'opioïde en tant que substances actives, leurs procédés de fabrication et leurs utilisations thérapeutiques | |
UY37518A (es) | Formas de dosificación de liberación modificada gastroretentivas para oprozomib y proceso para su fabricación | |
MX2021010558A (es) | Albumina de suero humano en formulaciones. | |
UY37413A (es) | Formulaciones de liberación inmediata de oprozomib | |
JP2016504390A5 (es) | ||
MX2019015927A (es) | Composiciones para administración de fármacos y métodos de uso de las mismas. | |
Sooryanarayana | Cinderella's lifetime abuse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |